Utility of 90-Day Mortality vs 30-Day Mortality as a Quality Metric for Transcatheter and Surgical Aortic Valve Replacement Outcomes | Zendy

Sameer Hirji | Zendy; Siobhan McGurk | Zendy; Spencer Kiehm | Zendy; Julius I. Ejiofor | Zendy; Fernando RamirezDel Val | Zendy; Ahmed A. Kolkailah | Zendy; Natalia Berry | Zendy; Piotr Sobieszczyk | Zendy; Marc Pelletier | Zendy; Pinak Shah | Zendy; Patrick T. O’Gara | Zendy; Tsuyoshi Kaneko | Zendy

Open Access

Utility of 90-Day Mortality vs 30-Day Mortality as a Quality Metric for Transcatheter and Surgical Aortic Valve Replacement Outcomes

Author(s) -

Sameer Hirji,

Siobhan McGurk,

Spencer Kiehm,

Julius I. Ejiofor,

Fernando RamirezDel Val,

Ahmed A. Kolkailah,

Natalia Berry,

Piotr Sobieszczyk,

Marc Pelletier,

Pinak Shah,

Patrick T. O’Gara,

Tsuyoshi Kaneko

Publication year - 2019

Publication title -

jama cardiology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.108

H-Index - 63

eISSN - 2380-6591

pISSN - 2380-6583

DOI - 10.1001/jamacardio.2019.4657

Subject(s) - medicine , valve replacement , aortic valve replacement , aortic valve , concomitant , emergency medicine , cardiology , stenosis

Questions have recently arisen as to whether 30-day mortality is a reasonable metric for understanding institutional practice differences after transcatheter aortic valve replacement (TAVR) and surgical aortic valve replacement (SAVR).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog